A New Standard for Precision Chemotherapy
Precision Chemo is developing a new approach to chemotherapy that integrates patient selection, treatment optimization, and monitoring to improve outcomes in metastatic cancer.
The Problem
Chemotherapy remains a cornerstone of treatment for patients with metastatic cancer. Despite decades of clinical use, most chemotherapies are still administered using generalized dosing strategies that do not account for individual patient biology or likelihood of response.
As a result, many patients are exposed to therapies that may be ineffective or unnecessarily toxic, while others who could benefit are not optimally treated. Clinicians are often forced to rely on trial-and-error approaches, adjusting treatment only after disease progression or adverse events occur.
At the same time, advances in precision oncology have largely bypassed traditional chemotherapies, creating a disconnect between modern biomarker-driven medicine and the treatments most patients actually receive.
Our Approach
Precision Chemo is modernizing chemotherapy by applying a precision oncology framework to established cancer therapies.
Rather than developing entirely new drugs, we focus on reformulating well-characterized chemotherapies and integrating patient selection and treatment monitoring into their clinical use. This approach is designed to better align therapy with individual patient biology and clinical response over time.
Our development strategy emphasizes:
Precision-guided treatment to identify patients most likely to benefit
Treatment optimization to support appropriate dosing and ongoing assessment
Clinical relevance by working with therapies that are already widely used in oncology practice
By combining established medicines with a precision-driven treatment strategy, we aim to better align chemotherapy with modern oncology and regulatory expectations.
The Science
Precision Chemo is built on the principle that chemotherapy response is biologically heterogeneous and can be better guided through objective, data-driven assessment.
Our scientific approach focuses on identifying biological signals associated with treatment response and integrating those insights into a structured framework for patient selection, treatment optimization, and monitoring. This framework is designed to inform clinical decision-making throughout the course of therapy, rather than relying solely on fixed dosing or delayed outcome measures.
The result is a precision-guided model that applies modern oncology principles to chemotherapies that remain central to cancer care.
Lead Indication & Pipeline
Precision Chemo’s initial development focus is metastatic Triple-Negative Breast Cancer (mTNBC), an area of significant unmet clinical need where chemotherapy remains a foundational treatment option.
Our strategy prioritizes indications where established chemotherapies play a central role in care and where a precision-guided approach has the potential to meaningfully inform treatment decisions.
Following our lead program, we plan to expand into additional metastatic cancer indications, including ovarian and lung cancer, leveraging a consistent scientific and development framework.
Why it Matters
For many patients with metastatic cancer, chemotherapy remains an essential part of care. Yet treatment decisions are often made with limited ability to predict who will benefit, how long to continue therapy, or when a change in approach is warranted.
A more precise way to guide chemotherapy has the potential to improve patient experience and support better-informed clinical decisions. By aligning therapy more closely with individual response, clinicians may be able to intervene earlier, adjust treatment more thoughtfully, and avoid prolonged exposure to ineffective therapy.
At a broader level, a precision-guided approach to chemotherapy may also support more efficient use of widely prescribed cancer treatments, with implications for healthcare systems focused on value, outcomes, and sustainability.
Precision Chemo is focused on advancing this shift—bringing modern precision oncology principles to therapies that continue to serve a large and underserved patient population.
Company & Leadership
Precision Chemo is a biotechnology company focused on modernizing chemotherapy through a precision-guided development approach.
The company is led by Warren Cresswell, Founder and Chief Executive Officer, who brings more than 25 years of leadership experience across clinical diagnostics, pharmaceuticals, and medical devices. He has held senior executive roles at multiple healthcare companies and previously served as CEO of Prometheus Laboratories, a Nestlé Health Science company, where he led the organization through significant growth and a successful multi-billion-dollar acquisition.
Precision Chemo is built on deep experience at the intersection of diagnostics, therapeutics, and clinical commercialization, with a disciplined focus on translating scientific insight into clinically meaningful solutions.
Partner With Us
Contact Information
info@precisionchemo.com
+1-805-914-7813
Precision Chemo, Inc.
P.O. Box 27046
San Diego, CA 92198